mortality, because the majority of patients requiring dialysis are unable to achieve renal recovery. 2, 5, 6 Due to the little of clinical trials conducted in severe RF requiring dialysis in MM, the effect factors of reversal of renal failure and recovery from hemodialysis dependenceareunknown.
Inthecurrentstudy,weexaminedclinicalfeaturesandresponse to therapy in newly diagnosed MM (NDMM) patients with severe RF requiring dialysis who received initial therapy including novel agents to evaluate the promising factors of recovery from dialysis dependence and investigate the prognostic impact of dialysis independence for survival results. Table 1 .
| MATERIAL S AND ME THODS

| Patients and methods
Renal function was assessed using the estimated glomerular filtration rate (eGFR), which was calculated by the simplified Modification of Diet in Renal Disease (MDRD) formula. 7 Renal failure requiring hemodialysis was defined as an eGFR < 15 mL/min/1.73 m 2 and on hemodialysis at initial diagnosis. In order to analyze data in our study, the patients were classified depending on renal function at diagnosis and response treatment: group 1: on dialysis at diagnosis improved to dialysis independence after therapy and group 2: on dialysis at diagnosis and remained dialysis dependence after treatment.
| Treatment
All patients received chemotherapy as first-line therapy and similar supportive care. Thirty-two patients (71.11%) received bortezomibbasedcombinations.Theregimenincludedbortezomibanddexamethasone (VD) in 68.75% of patients; bortezomib, cyclophosphamide, and dexamethasone(VCD)in25%;andbortezomib,melphalan,andprednisolone (VMP) in 6.25%. Thirteen patients (28.89%) received a thalidomide-based therapy as first-line chemotherapy. Therapy comprised thalidomide,melphalananddexamethasone(MPT)in69.23%ofpatients;thalidomide,cyclophosphamideanddexamethasone(CTD)in 15.38%;anddexamethasoneandthalidomide(TD)in15.38%.
The degree of recovery of renal function was estimated on the basisoftheInternationalMyelomaWorkingGroup(IMWG)criteria: 2, 3 AsustainedimprovementofbaselineeGFRto≥60mL/min/1.73m 2 was defined as renal complete response (CRrenal), a sustained improvement of baseline eGFR from < 15 to 30-59 mL/min/1.73 m 2 as renal partial response (PRrenal) and a sustained improvement of baseline eGFR of <15 mL/min/1.73 m 2 to 15-29 mL/min/1.73 m 2 or if baseline eGFR was 15-29 mL/min/1.73 m 2 , improvement to 30-59 mL/min/1.73 m 2 as renal minor response (MRrenal). Treatment response was evaluated at the date of termination of each treatment according to the standard IMWG criteria. 8 From the first day of treatment until the day of first confirmative, renal response (at least MRrenal) was estimated as time to renal response. From the first day of treatment until the day of first confirmative, maximum renal response was estimated as time to major renal response. From the first time of the discovery of renal insufficiency symptoms until the time ofinitialtreatmentofmyelomawasdefinedaskidneydiseasehistory.
The time from diagnosis until date of death or date of last followupwasestimatedasoverallsurvival(OS).Thetimefromtreatment initiation until date of progression, death, or last follow-up was estimatedasprogression-freesurvival(PFS).
| Statistical analysis
Mann-Whitney U test was used for the comparisons for continu- 
| RE SULTS
| Patient characteristics
In our study, the median age was 62 years (range: 44-83 years) and 15 patientswere≥70yearsoldatdiagnosis.Thirty-threepatients(73.3%) were male. The median eGFR was 7.25 mL/min/1.73 m 2 (range: 
| Response to chemotherapy
In the present study, at least very good partial response (VGPR) rate was 46.88% in patients received bortezomib-based regimens, and 23.08% TA B L E 1 Clinical and laboratory characteristics of 45 NDMM patients with severe renal failure requiring dialysis based on dialysis discontinuation or dependence after therapy dialysis independence was 89 days (range: 28-750 days) ( Figure 1C ).
All patients (n = 45)
Dialysis discontinuation after therapy (n = 22)
Dialysis dependence after therapy (n = 23) P-value
Then we analyzed for factors that could be related to probability of dialysis discontinuation among NDMM patients with serious renal impairment requiring hemodialysis (Table 1 ). In the univari- (Table 3 ).
| Survival outcomes
Early death occurred in 4 (8.89%) cases (within 2 months from treatment initiation 
| D ISCUSS I ON
Multiple myeloma (MM) is a malignancy of malignant plasma cells and occurs renal insufficiency in 20%-50% of patients. 5, 9 Up to 10% of MM patients can present with serious renal impairment requiring dialysis. 10 Renalfailureisrelatedtoagrowthriskofearlydeath andtreatment-relatedtoxicity. 2 Many studies have confirmed that renal failure and reversal of hemodialysis dependence can lead to enormous survival benefits. 5, 11, 12 Many studies have confirmed that bortezomib-based therapy was very effective for the treatment of MM patients with renal failure [14] [15] [16] [17] [18] and could reverse dialysis dependence. 10, 19 In our study, at least VGPR rate was 46.88% in patients received bortezomib-based therapy, and 23.08% for those treated with thalidomide-based com- 20, 21 It is essential to be able to recognize the symptoms of myeloma in clinical routine and to be aware of basic diagnostic features to confirm this disease and give timely treatment. [21] [22] [23] [24] In addition, β 2 -microglobulin (β 2 M) is expressed on the surface of all nucleated cell and associated with the major histocompatibility complex I (MHC-I)/human leukocyte antigen I (HLA-I) to facilitate antigen presentation. 25 β 2 M, which has been introduced into staging system of MM and thought to a reflection of renal function and the tumor cell burden, has been regarded as the most important prognostic factor in MM. 26, 27 Recent studies discovered that β 2 M is not only a biomarker in patients with chronic kidney disease and endstagerenaldisease,butalsoapromisingmarkertoassessglomerular and tubular function in adults. 28 However, our study first found the role of β 2 M in the reversal of renal failure and recovery from dialysis dependence.
ItisknowntousthatserumFLCassaysindiagnosticscreen-
ing panels were recommended currently by International Myeloma Working Group (IMWG). 29 In addition, Thomas et al illustrated that serum free light chains should be used to evaluate response in light chain multiple myeloma. 30 However, our study found the prognostic value of involved free light chain which was significantly related to reversibility from dialysis dependence. This is possibly associated with the monoclonal light chains on basement membranes of the glomeruli and/or the renal tubule which cause the reason of MM patients with renal impairment. 3, 31 In the meantime, Dimopoulos et al suggest that very high levels of FLCs were associated with a lower probability of RF recovery or dialysis discontinuation. 12, 13 Inaconclusion,ourdataindicatethattheshorterkidneydisease history, lower serum level of β2-microglobulin and free light chain, achieving at least VGPR is related to a high probability of hemodialysis discontinuation and bortezomib-based regimens were strongly recommended for treatment of MM patients requiring dialysis. In addition, recovery from dialysis dependence, proteinuria <3.5 g/24 h, and achieving at least VGPR can lead to enormous survival benefits in NDMM patients with serious renal impairment requiring hemodialysis. Our study offered instructions for treatment and evaluated prognosis of NDMM patients with severe renal failure requiring dialysis. 
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